NCT03150914View on ClinicalTrials.gov

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
LAMLymphangioleiomyomatosis
Interventions
DRUG

Sirolimus

mTOR inhibitor or placebo

Trial Locations (8)

19104

University of Pennsylvania, Philadelphia

20892

Brigham and Woman's Hospital, Boston

30322

Emory University, Atlanta

45174

University of Cincinnati, Cincinnati

60153

Loyola University, Chicago

94305

Stanford University, Palo Alto

98104

Swedish Health, Seattle

80206-2761

National Jewish Hospital, Denver

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

The LAM Foundation

OTHER

lead

University of Cincinnati

OTHER